GSK plc GSK on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Under the agreement, GSK will pay up to $2 billion in total cash consideration. This includes $1 ...

XDefiant executive producer Mark Rubin says developers like Activision are too focused on making the most money, instead of designing a good game that players naturally gravitate towards.

Those are just a few of the classic storylines Lifetime movie fans expect to see when they switch on the TV, and, this summer, GSK is adding another real-life danger to Lifetime's lineup ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival ...

GSK (NYSE:GSK) reported Q1 2025 results on Wednesday, narrowly beating analysts’ estimates as the British drugmaker’s Specialty Medicines business offset weakness in its Vaccine and General ...

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug ...

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then immediately hatched a plan to replace it with a late-stage candidate for metabolic dysfunction-associated steatohepatitis ...

GSK GSK1.80%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

(Reuters) - GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts and dual sourcing for its medicines, but offered few details.

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) GSK's acquisition of efimosfermin represents ...